Fatty acids and antioxidants in multiple sclerosis: Therapeutic role of GEMSP.

Fatty acids and antioxidants in multiple sclerosis: Therapeutic role of GEMSP.

Publication date: Mar 11, 2019

Multiple sclerosis is a high-frequency neurological disorder in young adults. Although there are some genetic and environmental factors that have been related to the onset of the disease, these are not still completely understood and nowadays multiple sclerosis can neither be prevented, nor its symptom effectively treated due to disease heterogeneity. For this reason, the search of prognostic factors and new therapeutic compounds for MS has long aroused among clinicians and researchers. Among these therapeutic compounds, GEMSP, which consists of a mixture of functional constituents as fatty acids, antioxidants, free radical scavengers and amino acids linked individually to poly-L-Lysine (PL), is emerging as a promising drug for MS treatment. Pre-clinical studies using GEMSP have demonstrated that this drug strongly inhibits brain leukocyte infiltration and completely abolishes experimental autoimmune encephalomyelitis. In addition, in an open clinical trial in humans treated with GEMSP, in 72% of the cases, a positive evolution of the state of the MS patients treated with GMSP was observed. In this review a biochemical characterization of main constituents of GEMSP, which include fatty acids as oleic acid, linoleic acid or azelaic acid and the antioxidants alpha-tocopherol or ascorbic acid, will be provided in order to understand their proved therapeutic effects in MS.

Ahumada-Pascual, P., Ga~n’an, D.G., Montero, Y.E.B., and Velasco, A. Fatty acids and antioxidants in multiple sclerosis: Therapeutic role of GEMSP. 17501. 2019 Curr Pharm Des.

Concepts Keywords
Amino Acids Alpha
Antioxidants Oleic acid
Ascorbic Acid Antioxidants
Biochemical Fatty acid
Brain Nutrition
Clinical Trial Organic compounds
Evolution Chemistry
Fatty Acids Branches of biology
Free Radical Scavengers MS
Frequency Neurological disorder
Genetic Nowadays multiple sclerosis
Heterogeneity Experimental autoimmune encephalomyelitis
Linoleic Acid
Multiple Sclerosis
Neurological Disorder
Oleic Acid


Type Source Name
drug DRUGBANK Ascorbic acid
drug DRUGBANK Vitamin E
drug DRUGBANK Azelaic acid
drug DRUGBANK Linoleic acid
drug DRUGBANK Oleic Acid
disease MESH experimental autoimmune encephalomyelitis
drug DRUGBANK L-Lysine
drug DRUGBANK Amino acids
disease MESH neurological disorder
disease DOID multiple sclerosis
disease MESH multiple sclerosis
pathway BSID Fatty acids


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *